Key result
Emerging Lp(a)-lowering trials face key design challenges in optimizing patient selection and clinical outcomes.
Why the study?
Lipoprotein(a) is a source of residual risk in patients with ASCVD, and challenges in clinical trial design for Lp(a)-lowering therapies need to be addressed to optimize patient selection and outcomes.
This review discusses the challenges and considerations in designing clinical trials for emerging Lipoprotein(a)-lowering therapies to optimize patient selection and outcomes in ASCVD.
Lipoprotein(a) [Lp(a)] is a source of residual risk in patients with atherosclerotic cardiovascular disease (ASCVD). Clinical trials of fully human monoclonal antibodies targeting proprotein convertase subtilisin kexin 9 have shown that reductions in Lp(a) concentrations may be a predictor of event reduction with this class of cholesterol-lowering therapy. With the advent of selective therapies targeting Lp(a) such as antisense oligonucleotides, small-interfering RNA-based therapies, and gene editing, lowering of Lp(a) may lead to reduction in ASCVD. The phase 3 Lp(a)HORIZON (Assessing the Impact of Lipoprotein(a) Lowering with TQJ230 on Major Cardiovascular Events in Patients With CVD) outcomes trial is currently testing the effect of pelacarsen, an antisense oligonucleotide, on ASCVD risk. Olpasiran is a small-interfering RNA that is in a phase 3 clinical trial. As these therapies enter clinical trials, challenges in trial design will have to be addressed to optimize patient selection and outcomes.
No takes yet. Share an insight, caveat, or question.
Malick et al. (2023) conducted a review in Atherosclerotic cardiovascular disease (ASCVD). Lipoprotein(a)-lowering therapies was evaluated. As selective lipoprotein(a)-lowering therapies like pelacarsen and olpasiran enter phase 3 clinical trials, challenges in trial design must be addressed to optimize patient selection and outcomes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: